Cytoreductive and Palliative Radical Prostatectomy, Extended Lymphadenectomy and Bilateral Orchiectomy in Advanced Prostate Cancer with Oligo and Widespread Bone Metastases: Result of Feasibility, Our Initial Experience

To evaluate the feasibility of cytoreductive radical prostatectomy (CRP), lymphadenectomy, and bilateral orchiectomy in patients with advanced prostate cancer with oligo- and poly-metastases. Furthermore, the functional and oncological outcomes of these patients in comparison with the control group that underwent treatment only with systemic therapy (ST group) is investigated in a well-selected, prospective cohort study. A total of 26 patients were enrolled in CRP group and 23 patients in ST group. The patients have been followed (9 to 43 months(median:19.5)) with PSA (prostate specific antigen), whole body bone scan and other necessary imaging and laboratory tests. Functional and oncological outcomes were compared between two groups. Biochemical relapse occurred in 9 patients (34.6%) in CRP group and in 17 patients (73.9%) in ST group (P = 0.01). Whole-body bone scans showed more reduced metastasis volume in CRP group (P = 0.003). There was no voiding dysfunction in 22 patients in CRP group post-operatively (84.6%), while in ST group trans-urethral resection of prostate or permanent Foley catheter was needed in 8 patients (34.7%) and bilateral percutaneous nephrostomy was done in one patient. Six patients in CRP group (23%) and eight patients in ST group (34.7%) died because of prostate cancer and there was no difference between cancer specific survival between the two groups (P = 0.975). Although surgery doesn’t improve cancer specific survival in patients with skeletal metastatic prostate cancer in the short term, but offers better local control, improves biochemical relapse-free survival, might prevent excessive interventions, and reduce bone pain and metastasis.